Previous 10 | Next 10 |
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma PR Newswire INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued an...
2023-11-06 14:00:35 ET More on POINT Biopharma Global Eli Lilly POINTs Toward Radiopharmaceutical Ambitions POINT Biopharma trades through deal price with Eli Lilly Eli Lilly to acquire Point Biopharma in $1.4B deal (update) Seeking Alpha’s Quant Ratin...
2023-10-18 13:16:41 ET More on POINT Biopharma Global Eli Lilly POINTs Toward Radiopharmaceutical Ambitions POINT Biopharma: Leading The Future Of Radioligand Therapy POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials Eli Lilly t...
2023-10-12 16:35:30 ET Summary Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, has driven significant revenue growt...
Originally published on the Pentair blog by Karla Robertson, EVP, General Counsel, Secretary and Chief Social Responsibility Officer NORTHAMPTON, MA / ACCESSWIRE / October 10, 2023 / Pentair / In recognition of our commitment to sustainability and demonstrated progress in making a...
NEW YORK, NY / ACCESSWIRE / October 10, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: POINT Biopharma Global, Inc. (NASD...
2023-10-06 13:09:10 ET More on Eli Lilly Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Eli Lilly: Don't Be Fooled By Greed Walmart says Ozempic, weight loss drugs impacting sales - Bloombe...
2023-10-05 16:50:42 ET Shares of Point Biopharma Global (NASDAQ: PNT) are up 86% this week as of Thursday's close, according to data provided by S&P Global Market Intelligence , after the radiopharmaceutical company agreed to be acquired by Eli Lilly (NYSE: LLY) ...
2023-10-05 02:41:08 ET Summary Eli Lilly has acquired POINT Biopharma Global in a $1.4 billion all-cash deal. POINT Biopharma Global generates modest revenue and experiences significant losses, but its focus on radioligand therapy aligns with Eli Lilly's oncology operations. T...
2023-10-03 18:33:22 ET Eli Lilly 's (NYSE: LLY) latest acquisition didn't exactly meet with widespread shareholder approval on Tuesday. After announcing that it signed a deal to acquire Point Biopharma Global (NASDAQ: PNT) , its share price headed south to end the day 2.4% l...
News, Short Squeeze, Breakout and More Instantly...
POINT Biopharma Global Inc. Company Name:
PNT Stock Symbol:
NASDAQ Market:
NORTHAMPTON, MA / ACCESSWIRE / June 25, 2024 / Pentair Greg Claffey, Group President, Pentair Pool (right) presents Pentair Pool Step Into Swim sponsorship check to Rowdy Gaines, Vice President Partnerships and Development, PHTA, and Olympic Gold Medalist. As published on the Pentair Blog . ...
LONDON, UK / ACCESSWIRE / April 18, 2024 / Pentair plc (NYSE:PNR), a leader in helping the world sustainably move, improve and enjoy water, life's most essential resource, today released its 2023 Corporate Responsibility Report, reporting on the Company's efforts and progress toward Making Bett...
Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceuti...